Tag:
Baxter International
Latest Headlines
Latest Headlines
ALSO NOTED: FDA says no to Indevus; Nektar gets sweetened deal with Baxter; Akela pulls public offering; and much more...
> Indevus Pharmaceuticals says that the FDA has turned thumbs down on its new therapy for bladder cancer, a move that trimmed its stock value. Valstar was pulled from the market five years ago
ALSO NOTED: Halozyme inks tech pact; Bioniche gains SPA; Ariad shares on rise; and much more...
> Halozyme Therapeutics has agreed to put its technology to work to develop a new formulation of Baxter's Gammagard Liquid for subcutaneous delivery. Gammagard is used to treat primary
SPOTLIGHT: Baxter bullish on Gammagard
Baxter International says that a preliminary analysis of data from a Phase II study of Gammagard for Alzheimer's has produced enough encouraging signs to lay the groundwork for Phase III. The next
